Dec 15 (Reuters) - Redhill Biopharma Ltd REDIF.PK :
* REDHILL'S PHASE 2/3 COVID-19 CANDIDATE OPAGANIB REDUCES ARDS-RELATED BLOOD CLOTTING IN PRECLINICAL MODEL
* REDHILL BIOPHARMA LTD - OPAGANIB DEMONSTRATED REDUCED THROMBOSIS IN A PRECLINICAL MODEL OF ARDS